Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRS1 siRNA
- Development stage
- Preclinical
- Lead developer
- insitro
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
IRS1 siRNA is a liver-targeted small interfering RNA (siRNA) therapeutic being developed by insitro for the treatment of metabolic dysfunction-associated liver disease (MASLD). Discovered through AI/ML-driven genetic analysis of UK Biobank data, the drug specifically targets insulin receptor substrate 1 (IRS1) in hepatocytes. By suppressing hepatic IRS1 expression, the siRNA reduces de novo lipogenesis (DNL) and hepatic triglyceride accumulation. Preclinical studies in human hepatocytes, diet-induced obesity (DIO) mice, and cynomolgus monkeys have demonstrated that a single dose can significantly reduce hepatic IRS1 levels and improve NAS scores without adversely affecting systemic glucose homeostasis.
- Other names
- liver-targeted siRNA against IRS1
02
Targets
IRS1 (Insulin receptor substrate 1)
Beyond the preview
Go deeper on IRS1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRS1 siRNA.